Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05730816 · ClinicalTrials.gov registry record · Phase 2
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
A Phase 2 study of Mesothelioma, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT05730816: Recruiting Phase 2 study of Mesothelioma, sponsored by Brigham and Women's Hospital.
NCT05730816 is a Phase 2 study of Mesothelioma that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 130 participants, below the 195-participant average among 46 other Mesothelioma trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05730816, a Phase 2 study of Mesothelioma, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .
Primary Outcome
The primary endpoint is the area under the curve (AUC) of SCr measured daily over 7 days in Mg- versus placebo-treated patients
Conditions Studied
Interventions
- DRUG Magnesium sulfate
- DRUG Normal Saline
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 2 |
What NCT05730816 shows while recruiting
NCT05730816 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 195-participant average among 46 other Mesothelioma trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which Magnesium sulfate is the first listed.
NCT05730816 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05730816 about?
NCT05730816 is a clinical study titled "MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI". In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .
What is the current status of trial NCT05730816?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2023-04-04. Estimated completion is 2028-01-01.
What conditions does trial NCT05730816 study?
This clinical trial studies the following conditions: Mesothelioma.
What interventions are being tested in trial NCT05730816?
The interventions under investigation include: Magnesium sulfate (DRUG), Normal Saline (DRUG).
Who is sponsoring clinical trial NCT05730816?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05730816 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05730816's enrollment target sits among peer trials
130 20th of 46 higher than 27 of 46 other Mesothelioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Olaparib in Patients With HRD Malignant Mesothelioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI